^
    Back
    Association details:
    Biomarker:POU5F1 expression
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:cisplatin (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Oral Oncol
    Title:

    Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma

    Published date:
    03/01/2022
    Excerpt:
    OCT4 expression in HNSCC tumors was associated with radioresistance. However, combination therapy with cisplatin was found to overcome thisradioresistance in OCT4-expressing HNSCC tumors....Ex vivo drug sensitivity analysis of HNSCC tumors confirmed the association between OCT4 expression and cisplatin sensitivity.
    DOI:
    10.1016/j.oraloncology.2022.105772